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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a major cause of serious
infections in hospitals and in the community worldwide. In this study, MRSA isolated from patients in
Kuwait hospitals were analyzed for resistance trends and the genetic location of their resistance
determinants.
Methods: Between April 1994 and December 2004, 5644 MRSA isolates obtained from different clinical
samples were studied for resistance to antibacterial agents according to guidelines from the National
Committee for Clinical Laboratory Standards and the British Society for Antimicrobial Chemotherapy.
The genetic location of their resistance determinants was determined by curing and transfer experiments.
Results: They were resistant to aminoglycosides, erythromycin, tetracycline, trimethoprim, fusidic acid,
ciprofloxacin, chloramphenicol, rifampicin, mupirocin, cadmium acetate, mercuric chloride, propamidine
isethionate and ethidium bromide but susceptible to vancomycin, teicoplanin and linezolid. The proportion
of the isolates resistant to erythromycin, ciprofloxacin and fusidic acid increased during the study period.
In contrast, the proportion of isolates resistant to gentamicin, tetracycline, chloramphenicol and
trimethoprim declined. High-level mupirocin resistance increased rapidly from 1996 to 1999 and then
declined. They contained plasmids of 1.9, 2.8, 3.0, 4.4, 27 and 38 kilobases. Genetic studies revealed that
they carried plasmid-borne resistance to high-level mupirocin resistance (38 kb), chloramphenicol (2.8 –
4.4 kb), erythromycin (2.8–3.0 kb) and cadmium acetate, mercuric chloride, propamidine isethionate and
ethidium bromide (27 kb) and chromosomal location for methicillin, the aminoglycosides, tetracycline,
fusidic acid, ciprofloxacin and trimethoprim resistance. Thus, the 27 kb plasmids had resistance phenotypes
similar to plasmids reported in MRSA isolates in South East Asia.
Conclusion: The prevalence of resistance to erythromycin, ciprofloxacin, high-level mupirocin and fusidic
acid increased whereas the proportion of isolates resistant to gentamicin, tetracycline, chloramphenicol
and trimethoprim declined during the study period. They contained 27-kb plasmids encoding resistance to
cadmium acetate, mercuric chloride, propamidine isethionate and ethidium bromide similar to plasmids
isolated in MRSA from South East Asia. Molecular typing of these isolates will clarify their relationship to
MRSA from South East Asia.
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Background
Methicillin-resistant  Staphylococcus aureus (MRSA) has
continued to be a major pathogen causing infections in
hospitals and in the community and are increasingly iso-
lated in hospitals worldwide. Following its initial isola-
tion in the UK in 1961, many outbreaks of infections due
to MRSA have occurred and it has now become endemic
in several centers in the world [1-3]. MRSA were initially
associated with large teaching hospitals, but they now also
colonize or cause infections in patients in smaller health
care facilities, nursing homes, general hospitals [2,3] and
in the community [3-6]. MRSA are important because, in
addition to being methicillin or oxacillin- resistant, most
of them are also resistant to commonly used antibiotics.
There is evidence that antibacterial resistance is associated
with an increased length of hospital stay, increased finan-
cial burden [7] and increased mortality [8] associated with
infection in the hospitalized patient. Therefore, knowl-
edge of the susceptibility patterns of local strains is essen-
tial for the judicial use of antibacterial agents for empiric
therapy
Some MRSA strains, known as epidemic MRSA (EMRSA),
can spread rapidly between patients within and between
hospitals thereby causing major problems for infection
control [1-3,9,10]. The incidence of MRSA differs in differ-
ent hospitals, states or countries. Even within the same
hospital, their incidence may differ between wards. MRSA
also differ in their resistance to antibacterial agents and in
the genetic location of these resistance determinants.
Studies have shown that the genetic determinants for anti-
biotic resistance reside on plasmids, chromosomal DNA
or on transposable elements [11,12]. The acquisition or
loss of these genetic determinants may contribute to
changes in the resistance patterns in a particular environ-
ment. Changes in resistance patterns can also be due to
the introduction of different resistant clones to a health-
care facility by healthcare workers or patients [13]. In this
report, we present the results of studies conducted on
MRSA isolated from Kuwait hospitals from 1994 to 2004




The MRSA isolates for this study were submitted for typing
to the MRSA Reference Laboratory situated at the Depart-
ment of Microbiology, Faculty of Medicine, Kuwait Uni-
versity, Kuwait. A total of 5,644 consecutive MRSA isolates
were received for typing and antibiotic susceptibility test-
ing between 1994 and 2004. They were identified by cul-
tural characteristics, Gram's stain, and positive tube
coagulase and DNase tests in the individual laboratories
and pure cultures were sent to the reference laboratory for
mecA PCR and typing. The isolates were preserved in glyc-
erol 15% (v/v) in brain heart infusion broth (BHIB,
Oxoid, Basingstoke, UK) at -80°C. They were recovered by
subculturing in BHIB at 35°C for 24 hr followed by two
further subcultures on brain heart infusion agar. This
study was performed with funds from projects MI 088, MI
091 and MI 01/03 from Kuwait University Research
Administration. This study did not require the approval of
the university ethics committee.
Susceptibility to antimicrobial agents
Susceptibility to antimicrobial agents was determined by
the disk diffusion method [14] on Mueller-Hinton Agar
(Oxoid, UK) incubated for 24 hr at 35°C. The following
antibiotic disks (Oxoid) were used: oxacillin (1 µg), ben-
zyl penicillin (2U), kanamycin (30 µg), neomycin (30
µg), streptomycin (30 µg), tobramycin (10 µg), mupi-
rocin (200 µg), gentamicin (10 µg), erythromycin (15 µg),
chloramphenicol (30 µg), tetracycline (10 µg), trimetho-
prim (2.5 µg), fusidic acid (10 µg), rifampicin (5 µg), cip-
rofloxacin (5 µg), teicoplanin (30 µg), vancomycin (30
µg), linezolid (30 µg). Susceptibility to fusidic acid was
performed according guidelines by the British Society for
Antimicrobial Chemotherapy [15]. For susceptibility to
non antibiotics, disks containing the agents were prepared
in the laboratory with the following concentrations: cad-
mium acetate (50 µg), mercuric chloride (109 µg), propa-
midine isethionate (100 µg) and ethidium bromide (120
µg) [16].
Minimum inhibitory concentration (MIC) of oxacillin,
mupirocin, vancomycin and teicoplanin were determined
using E-test strips (AB Biodisk, Solna, Sweden) according
to the manufacture's instructions. Methicillin resistance
was confirmed by detecting the amplification of the mecA
gene from 1994–2000 and by the detection of PBP 2a
gene product using a rapid latex agglutination kit (Denka-
Seiken, Japan) according to the manufacturer's instruction
from 2001 to 2004.
Amplification of the mecA gene
The mecA gene for methicillin resistance was amplified
using primers purchased from Gibco BRL (Life Science
Technologies, UK). The description of the primers and
methods have been published previously [17].
Genetic location of resistance determinants
Plasmids were isolated by the cetyltrimethylammonium
bromide method as described previously [18] and sepa-
rated by agarose gel electrophoresis. The genetic location
of the resistance determinants was studied by curing and
transfer experiments as described previously [18].
For curing of resistance and plasmids, the isolates were
incubated on BHIA at 45°C for 48 hr and single colonies
of each isolate were screened by replica plating for the lossBMC Infectious Diseases 2006, 6:168 http://www.biomedcentral.com/1471-2334/6/168
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of resistance. At least 300 colonies were screened for each
isolate. Loss of resistance was confirmed by disk diffusion
tests. Colonies that lost antimicrobial resistance were
screened for plasmid loss by agarose gel electrophoresis.
For the transfer of resistance and plasmids, representative
isolates were selected based on their resistance and plas-
mid profiles and used as donors in conjugation and
mixed-culture transfer (MCT) experiments using strains
WBG541 and WBG1876 as recipients respectively as
described previously [18]. Selections for transconjugants
and transcipients were made on brain heart infusion agar
containing (mg/L) fusidic acid (5), rifampicin (2.5) and
one of the following agents: tetracycline (10), erythromy-
cin (5), Chloramphenicol (10), mupirocin (10), trimeth-
oprim (5), cadmium acetate (60), propamidine
isethionate (100). Transconjugants or transcipients were
screened for plasmid carriage by agarose gel electrophore-
sis.
Results
A total of 5,644 MRSA isolates were tested from 14 hospi-
tals in Kuwait between 1994 and 2004. The number of
isolates received yearly varied from 342 in 1994 to 930 in
2004. This was due to the increase in the number of labo-
ratories submitting MRSA for typing from four in 1994 to
14 in 2004. All of them contained the mecA DNA and were
resistant to the agents summarized on Table 1 but were all
susceptible to vancomycin, teicoplanin and linezolid.
Rifampicin resistance remained low throughout the study
period with a small increase observed in 2000. In contrast,
resistance to fusidic acid, ciprofloxacin and erythromycin
showed increasing trends. The prevalence of fusidic acid
resistance increased from 22% in 1994 to 92% in 2004.
The prevalence of erythromycin resistance increased from
66% in 1994 to 88% in 2004. The proportion of MRSA
isolates resistant to ciprofloxacin increased from 53% in
1994 to 92% in 2004 after a peak of 96% in 2002. On the
contrary, resistance to chloramphenicol, trimethoprim,
gentamicin, kanamycin, streptomycin, tetracycline
showed decreasing trends. The prevalence of trimetho-
prim resistance declined from 86% in 1994 to 27% in
2004. Chloramphenicol resistance decreased from 25% in
1994 to 2% in 2004. The proportion of isolates resistant
to gentamicin decreased from 98% in 1994 to 77% in
2001 before increasing to 81% in 2001. Similarly, the pro-
portion of isolates resistant to kanamycin and streptomy-
cin decreased although they were still above 80 percent.
High level mupirocin resistance increased from 6% in
1996 and peaked at 28% nationally in 1999 before it
declined to 1.0 % in 2003 and increased again to 4.7% in
2004. The prevalence of high -level mupirocin resistance
was higher in some hospitals, especially at the Burn unit
where it had reached 56% in 1997 [16]. Resistance to cad-
mium acetate, mercuric chloride, propamidine isethion-
ate and ethidium bromide remained high with slight
annual fluctuations.
Susceptibility to vancomycin and teicoplanin
Following the reports of vancomycin intermediate resist-
ance in MRSA in 1997 [19], vancomycin and teicoplanin
MIC were determined for all MRSA isolates submitted to
the typing laboratory from 1997. All of the isolates exam-
ined from 1997 to 1998 had vancomycin and teicoplanin
MIC values of 0-5-2 mg/L. However, from 1999, reduced
susceptibility to both vancomycin and teicoplanin (MIC:
3–4 mg/L) started to appear. The results of the isolates
tested between 1999 and 2004 are summarized in Table 2.
Plasmid analysis of MRSA isolates
Plasmid DNA was detected in all of the MRSA isolates. The
plasmids ranged in size from c2.0 kb to 38.0 kb and the
Table 1: Antibacterial resistance of MRSA isolates, 1994–2004.
Year Antibacterial resistance in MRSA (%)
# Gm Km Sm Em Cm Tet Tp Cip Fa Rf MupH Cd*
1994 342 98 100 100 66 25 94 86 53 22 1.0 ND 100
1 9 9 5 2 9 8 9 59 8 1 0 0 8 92 59 28 72 34 51 . 4 N D 9 8
1996 421 100 100 100 68 44 94 93 41 32 3.0 6.0 100
1997 245 94 99 99 81 23 95 75 72 57 5.0 17 97
1998 329 88 95 77 74 21 92 61 63 75 3.0 24 94
1999 336 84 92 92 69 4.0 93 38 79 89 2.0 28 94
2000 542 86 95 94 76 3.0 89 34 72 81 8.0 22 98
2001 533 77 88 89 86 2.0 79 37 81 88 1.0 2.7 94
2002 883 85 95 89 88 4.0 90 16 96 90 5.0 3.0 93
2003 785 77 88 89 86 4.0 88 17 88 85 1.0 1.0 91
2004 930 81 89 86 88 2.0 88 27 92 92 4.7 4.7 89
Abbreviations: #, number of isolates Gm, gentamicin, Km, kanamycin, Sm, streptomycin, Em, erythromycin, Cm, chloramphenicol, Tet, 
tetracycline, Tp, trimethoprim, Cip, ciprofloxacin, Fa, fusidic acid, Rf, rifampicin, MupH, high-level mupirocin resistance, Cd, cadmium acetate, also 
resistant to mercuric chloride, propamidine isethionate and ethidium bromide, ND, not detectedBMC Infectious Diseases 2006, 6:168 http://www.biomedcentral.com/1471-2334/6/168
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number of plasmids in each cell varied between two and
four. The plasmid contents of representative MRSA iso-
lates are presented in Figures 1 and 2. All carried a 27 kb
plasmid. The isolates differed in the carriage of the 38.0,
3.0, 4.4 and 2.8 kb plasmids. Approximately 60 % of them
contained three plasmids with sizes of 27, 3–4 and 2.8
kilobases (Figure 1), 30% of them contained two plas-
mids of 27 and 3–4 kilobases and approximately 10% of
them carried four plasmids. The 38.0 kb plasmid was
present only in isolates that expressed high-level mupi-
rocin-resistance (Figure 2).
Genetic location of antibacterial resistance determinants
Representative isolates having different resistance and
plasmid patterns were selected and used in curing and
transfer experiments to ascertain the genetic location of
the different resistance determinants. In curing experi-
ments, resistance to cadmium, mercuric chloride, propa-
midine isethionate and ethidium bromide were always
lost together with the loss of the 27 kb plasmids. The loss
of chloramphenicol resistance in chloramphenicol resist-
ant isolates corresponded to the loss of 4.4 kb plasmids.
The isolates were studied further by using them as donors
in mixed-culture transfer and conjugation experiments to
isolate and characterize their plasmids. Representatives of
the plasmids and resistance transferred are presented in
Table 3. In mixed-culture transfer experiments, resistance
to chloramphenicol, erythromycin, cadmium acetate,
mercuric chloride, propamidine isethionate and ethidium
bromide were transferred. The transfer of resistance to
cadmium acetate, mercuric chloride, propamidine
isethionate and ethidium bromide was accompanied by
the transfer of a 27 kb plasmid. Three different plasmid
sizes were associated with chloramphenicol resistance. It
was co – transferred with a 2.8 kb and a 3.5 kb plasmids
in mupirocin-susceptible isolates and co transferred wit a
4.4 kb plasmid in the high-level mupirocin resistant iso-
lates. In these isolates, the 4.4 kb plasmid could be trans-
ferred in both mixed-culture and conjugation
experiments. The transfer of erythromycin resistance was
accompanied by the transfer of 2.8 kb plasmid except in
one isolate obtained in 1995 where erythromycin resist-
ance was transferred together with a 3.0-kb plasmid. In
some instances, erythromycin resistance was transferred
but no plasmids were detected in the transcipients.
High-level mupirocin resistance was transferred in conju-
gation as well as in mixed-culture transfer experiments
and its transfer was accompanied by the transfer of a 38 kb
plasmid. Chloramphenicol resistance was co transferred
with high-level mupirocin resistance in conjugation
Plasmid content of mupirocin-susceptible MRSA, Lanes 1–6,  representatives of multiresistant MRSA carrying the 27 kb  plasmid encoding resistance to cadmium acetate, mercuric  chloride, propamidine isethionate and ethidium bromide and  the 2.8–3.0 kb plasmids Figure 1
Plasmid content of mupirocin-susceptible MRSA, Lanes 1–6, 
representatives of multiresistant MRSA carrying the 27 kb 
plasmid encoding resistance to cadmium acetate, mercuric 
chloride, propamidine isethionate and ethidium bromide and 
the 2.8–3.0 kb plasmids. Lane 7, a representative of non mul-
tiresistant MRSA. Lane 8, S. aureus strain WBG4483 contain-
ing plasmid molecular weight standards. Sizes are in kb.
Table 2: Susceptibility of MRSA isolates to vancomycin and teicoplanin
Vancomycin MIC (%) Teicoplanin MIC (%)
S/N Year # ≤ 2 mg/L 3 mg/L 4 mg/L ≤ 2 mg/L 3 mg/L 4 mg/L
1 1999 336 199(59.2) 120(35.7) 17(5.1) 225(70.0) 99(29.5) 12(3.5)
2 2000 542 494(91.1) 47(8.7) 1(0.2) 479(88.4) 58(10.7) 5(0.9)
3 2001 533 385(72.2) 133(25.0) 15(2.8) 293(55.0) 160(30.0) 80(15.0)
4 2002 884 773(87.4) 107(12.1) 4(0.5) 740(83.7) 112(12.7) 32(3.6)
5 2003 785 653(83.2) 132(16.8) 0.00 623(79.4) 162(20.6) 0.00
6 2004 930 807(86.8) 121(13.0) 2(0.2) 740(79.6) 176(18.9) 14(1.5)
Total 4010 3311(82.5) 660(16.5) 39 (1.0) 3100 (77.3) 767(19.1) 143(3.6)BMC Infectious Diseases 2006, 6:168 http://www.biomedcentral.com/1471-2334/6/168
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Plasmid contents of high-level mupirocin-resistantisolates Lanes 1, 3, 4, 5, 6, 9, 10 contained the 38-kb mupirocin resistance  plasmid and 4.4 kb chloramphenicol resistance plasmid in addition to the 27 kb plasmids Figure 2
Plasmid contents of high-level mupirocin-resistantisolates Lanes 1, 3, 4, 5, 6, 9, 10 contained the 38-kb mupirocin 
resistance plasmid and 4.4 kb chloramphenicol resistance plasmid in addition to the 27 kb plasmids. Sizes are in kb.BMC Infectious Diseases 2006, 6:168 http://www.biomedcentral.com/1471-2334/6/168
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experiments whether the transconjugants were selected on
plates containing mupirocin or chloramphenicol. Resist-
ance to gentamicin, kanamycin, streptomycin, tetracy-
cline, fusidic acid, trimethoprim and ciprofloxacin could
not be transferred in either mixed-culture transfer or con-
jugation experiments.
Restriction endonuclease digests of plasmids encoding 
resistance cadmium acetate, propamidine isethionate and 
ethidium bromide
The 27 kb plasmids were digested with EcoRI restriction
endonuclease and their restriction patterns compared.
The results presented in Table 3 showed that they were of
two closely related types. The first type consisted of plas-
mids, pXU01, pXU02 and pXU04 with EcoRI restriction
fragments sizes of 10.4, 6.4, 4.1, 2.6, 2.3 and 1.3 kilo-
bases. The second type consisted of plasmids pXU08 and
pXU09 that were isolated from isolates expressing high-
level mupirocin resistance. They had EcoRI restriction frag-
ment sizes of 11.5, 6.4, 3.5, 2.6, 2.3 and 1.3 kilobases. The
two types differed only in the sizes of two fragments.
Discussion
Methicillin – resistant Staphylococcus aureus continues to
be a major cause of problems in hospitals and in the com-
munity [1-3,6]. Although several studies have docu-
mented the increasing prevalence of MRSA worldwide
[20-26], reports documenting resistance trends in them
are scanty [23,27]. This report details antibacterial resist-
ance trends and their genetic determinants in MRSA iso-
lated in Kuwait hospitals from 1994 to 2004.
Most of them were resistant to the aminoglycosides, mac-
rolides, tetracyclines, trimethoprim, ciprofloxacin, fusidic
acid, heavy metal ions and nucleic acid-binding com-
pounds [16] with resistance profiles similar to the epi-
demic MRSA isolates from the UK (EMRSA1), Australia
(EA MRSA), Singapore and Malaysia obtained in the late
1980s and early 1990s [12,28,29]. Although no interme-
diate vancomycin resistant isolate (MIC: 8–16 mg/L) was
found during the study period, 17.5% and 22.7.1% of the
isolates demonstrated reduced susceptibility to vancomy-
cin and teicoplanin respectively (MIC: 3–4 mg/L) (Table
2). This is of concern and warrants closer observation to
detect any further increases in glycopeptides MIC levels.
Analysis of the resistance patterns revealed interesting
trends. While resistance to erythromycin, ciprofloxacin
and fusidic acid increased, others such as chlorampheni-
col, trimethoprim, and gentamicin declined over time
while the proportion of rifampicin-resistant isolates
remained low. The proportion of MRSA isolates resistant
to ciprofloxacin increased from 53% in 1994 to 92% in
2004. An increase in the proportion of MRSA isolates
resistant to ciprofloxacin (from 4.9% in 1998 to 75.9% in
1999) was also observed in MRSA isolated in Australian
teaching hospitals from1998 to1999 [27]. Similarly, a
study of antibiotic resistance in UK hospitals also reported
an increase in ciprofloxacin resistance from 14.9% to
23.8% in a 12 month period [30]. Furthermore, changes
in the prevalence of trimethoprim resistance in this study
were similar to that observed in the Australian study
where trimethoprim resistance also declined from 98.4%
in 1989 to 82.4% in 1999 [27].
Fusidic acid resistance showed an increasing trend with
the proportion resistant isolates increasing from 22% in
1994 to 92% in 2004. These levels of fusidic acid-resistant
MRSA in Kuwait hospitals are higher than what is reported
in many centers worldwide [31-33]. Although fusidic acid
resistance can arise readily by mutation in the laboratory,
its incidence in clinical MRSA isolates is still relatively low
Table 3: Properties of plasmids isolated from MRSA isolates
S/N Plasmids Size, kb Resistance phenotype Transfer Mode* EcoRI Restriction pattern
1 pXU01 27.1 Cd,Hg,Pi,Eb M 10.4, 6.4, 4.1, 2.6, 2.3, 1.3
2 pXU02 27.1 Cd,Hg,Pi,Eb M 10.4, 6.4, 4.1, 2.6, 2.3, 1.3
3 pXU04 27.1 Cd,Hg,Pi,Eb M 10.4, 6.4, 4.1, 2.6, 2.3, 1.3
4 pXU08 27.6 Cd,Hg,Pi,Eb M 11.5, 6.4, 3.5, 2.6, 2.3, 1.3
5 pXU09 27.6 Cd, Hg,Pi,Eb M 11.5, 6.4, 3.5, 2.6, 2.3, 1.3
6 pXU12 31.5 mupH C 7.8, 6.6, 6.1,4.9, 2.7, 1.8, 1.6
7 pXU16 38.0 mupH C, M ND
8 pXU17 38.0 mupH C,M ND
9 pXU03 2.8 Cm M ND
10 pXU11 3.5 Cm M ND
11 pXU14 4.4 Cm M, C ND
12 pXU07 2.8 Em M ND
13 pXU13 3.0 Em M ND
Abbreviations: Cd, cadmium acetate, Cm, Chloramphenicol, Eb, ethidium bromide, Em, erythromycin, Hg, mercuric chloride, Pi, propamidine 
isethionate, mupH, high-level mupirocin, ND, not done.
*, M, mixed culture transfer; C, conjugation.BMC Infectious Diseases 2006, 6:168 http://www.biomedcentral.com/1471-2334/6/168
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despite increasing reports worldwide [31-33]. High levels
of fusidic acid have been previously associated with areas
of hospitals where cross infection is common suggesting
the spread of a resistant clone [32]. A review of fusidic acid
consumption in two Kuwait hospitals revealed that an
average of 650 g of oral fusidic acid was consumed annu-
ally in these hospitals [34]. This may have contributed to
the emergence of fusidic acid resistance in the first place.
It was also demonstrated by pulsed-field gel electrophore-
sis that the fusidic acid -resistant MRSA in Kuwait hospi-
tals belonged to few genetic backgrounds [34]. The
transmission of these clones and their maintenance in the
different hospitals may explain their high prevalence in
Kuwait hospitals. Furthermore, the presence of fusidic
acid resistance in both multiresistant and non multiresist-
ant MRSA isolates this study supports the heterogeneous
mode of acquisition of resistance.
Although the overall prevalence of gentamicin resistance
was high throughout the study period, it declined over
time from 98% in 1994 to 80% in 2004 (Table 1). This
decline, which started in about 1998 appeared to have
coincided with the emergence of non multiple resistant
MRSA isolates including community -associated MRSA in
Kuwait hospitals which was not fully appreciated till 2000
[35]. It is now well established that community-acquired
MRSA is an increasing problem in the community as well
as in hospitals [6,33,35].
High-level mupirocin resistance was first reported in
MRSA isolated from a patient in a Burns unit in Kuwait
five years after mupirocin was introduced for clinical use
in Kuwait, in 1992 [36] due to the acquisition of a 38-kb
conjugative plasmid encoding high level mupirocin resist-
ance by a previously mupirocin-susceptible MRSA in the
Burns unit. The high-level mupirocin-resistant MRSA
clone then spread to other hospitals [37,38] and the pro-
portion of high-level mupirocin resistant MRSA increased
sharply from 6% in 1996 to 28% in 1999 and then
declined to 4% in 2004 following the restriction of mupi-
rocin use and the disappearance of the resistant clone. The
prevalence of MRSA resistant to mupirocin has also been
reported to decline following mupirocin withdrawal in a
USA hospital [39].
Results of studies to determine the genetic location of the
resistance determinants revealed that the multiresistant
MRSA isolates carried plasmid-mediated resistance to
chloramphenicol, high-level mupirocin, erythromycin,
cadmium acetate, mercuric chloride, propamidine
isethionate and ethidium bromide. Resistance to cad-
mium acetate, mercuric chloride, propamidine isethion-
ate and ethidium bromide were linked and carried on
closely related 27 kb plasmids (Table 3). These plasmids
have resistance phenotypes similar to plasmids present in
MRSA isolated in Singapore, Malaysia and other South
East Asian countries [12,28,29] but differed from plas-
mids found in the classic MRSA isolated in the 1960
and1970s which carried plasmid-borne resistance to tetra-
cycline, low level streptomycin resistance and penicilli-
nase production [12]. These results indicated that
resistance to methicillin, gentamicin, kanamycin, strepto-
mycin; trimethoprim and ciprofloxacin were located on
the bacterial chromosome similar to the Eastern Austral-
ian MRSA [27,29]. These results suggest that the most
common MRSA types in Kuwait hospitals appear to be
related to MRSA isolated in South East Asia [12,28].
Molecular typing with multi locus sequence analysis will
help clarify this relationship.
Conclusion
This study has demonstrated the changing prevalence of
antibiotic resistance in MRSA in Kuwait and determined
the genetic location of their resistance determinants. In
addition, it has highlighted the different factors contribut-
ing to the high prevalence of MRSA in Kuwait. These fac-
tors include (i) the persistence of multiply resistant MRSA
clones demonstrated by the high prevalence of multiply
resistant isolates and their spread among the hospitals
[38], (ii) the acquisition, transmission and subsequent
loss of the 38-kb plasmid encoding high-level mupirocin
resistance and (iii) the introduction and apparent trans-
mission of non multiresistant MRSA including EMRSA-15
and community acquired MRSA in Kuwait hospitals [35].
Therefore efforts must continue to be exerted to minimize
further selections and spread of new MRSA clones.
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